SpeeDx Pty. Ltd.
Suite G16, National Innovation Centre, Australian
4 Cornwallis Street
Eveleigh
Sydney
NSW 2015
Tel: 61-0-2-9209-4170
Website: http://www.speedx.com.au/
Email: sales@speedx.com.au
About SpeeDx Pty. Ltd.
Based in Sydney, Australia and founded in 2009, SpeeDx is a privately owned company specializing in innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. SpeeDx has a portfolio of market leading detection and priming technologies to enable new healthcare paradigms based on improved delivery and reduced costs. SpeeDx has a proven track record of scientific discovery and strives to provide cutting edge clinically relevant tools for the clinical diagnostic market.YEAR FOUNDED:
2009
LEADERSHIP:
CEO: Colin Denver
CSO: Alison Todd
CFO: Jennifer Maher
FOLLOW SPEEDX:
Tweets by SpeeDx
31 articles about SpeeDx Pty. Ltd.
-
SpeeDx Expand COVID-19 Diagnostics to Include Self-Collected Samples
4/21/2022
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have added saliva to the list of validated samples for their PlexPCR® SARS-CoV-2 qPCR diagnostic for COVID-19 sales across Europe#.
-
SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
10/6/2021
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest.
-
SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline
8/17/2021
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the SARS-CoV-2 Delta variant of concern.
-
SpeeDx Receives Clearance for COVID-19 Diagnostic Test
8/11/2021
SpeeDx Pty. Ltd. announced their PlexPCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration.
-
SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis
7/26/2021
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern.
-
SpeeDx and MolGen Announce Partnership for COVID-19 Test Solution
6/30/2021
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific.
-
Biopharma and life sciences from across the globe provide updates on their businesses and pipelines.
-
SpeeDx Receives CE-IVD Mark for PlexPCR® SARS-CoV-2
4/26/2021
New robust design COVID-19 test performs well against all known virus variants while supporting surging demand for reliable tests
-
Microbix & SpeeDx Form Exclusive CollaborationFocus on Diagnostics and Controls for Anti-Microbial Resistant Infections
4/26/2021
Microbix Biosystems Inc., a life sciences innovator and exporter, and SpeeDx Pty. Ltd., a developer of innovative molecular diagnostics solutions, are pleased to announce the formation of a collaboration under which Microbix will be exclusive developer of Quality Assessment Products to facilitate the registration and commercialization of SpeeDx diagnostic assays.
-
SpeeDx Increase Distribution Network
3/18/2021
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx ResistancePlus® and PlexPCR® tests.
-
SpeeDx Partners with Nepean Hospital to Commercialise Respiratory Virus Host Biomarker Assay
11/9/2020
Test will be deployable to support risk-based management of COVID-19, Influenza and other severe respiratory disease
-
SpeeDx and Nepean Hospital Awarded Federal Funding for Viral Respiratory Biomarker Test - Sep 03, 2020
9/3/2020
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, in partnership with researchers from Nepean Blue Mountains Local Health District’s Nepean Hospital Intensive Care Unit were awarded funding through the MTPConnect Biomedical Translation Bridge program.
-
SpeeDx and Roche Partner to Expand Access to Antibiotic Resistance Tests
6/16/2020
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics, in a non-exclusive agreement to expand global access to SpeeDx infectious disease and antibiotic resistance tests and technology. This press release featu
-
SpeeDx Pty. Ltd. Raises Additional $15 million in Series B Funding
2/11/2020
Feb. 11, 2020 13:00 UTC Funds to support expanding global menu and further U.S. clinical trial activities SYDNEY--( BUSINESS WIRE )-- SpeeDx Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, today announced it has raised $15 million in additional series B equity investment from U.S.-based Northpond Ventures. This investment comes with a company value uptick of 21.22%. This press release features multimedia. View the full rele
-
FIND Collaborates with SpeeDx and QuantuMDx
11/7/2019
Investigating feasibility of rapid, low-cost STI diagnostics development.
-
SpeeDx Pty. Ltd. Raises $15 Million From U.S. Investment Partnership
8/5/2019
SpeeDx Pty. Ltd., the developer of transformative new molecular diagnostic solutions, today announced it had raised up to US $10 million in additional equity investment from US-based Northpond Ventures
-
SpeeDx announce a collaborative agreement with GSK to supply tests and technology
6/24/2019
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product developmen
-
SpeeDx Receives FDA Breakthrough Designation for ResistancePlus® GC
6/11/2019
New diagnostic test enables antibiotic resistance testing and stewardship in gonorrhea treatment
-
SpeeDx Receives Clearance for PlexPCR Respiratory Virus Test
5/13/2019
Highly multiplexed test offers workflow advantages to support the Flu season surge
-
CORRECTING and REPLACING SpeeDx and Cepheid Announce Test Partnership
4/28/2019
SpeeDx tests will be available through Cepheid’s FleXible Cartridge programme for the GeneXpert System